Latest Lynx1 Capital Management LP Stock Portfolio
Lynx1 Capital Management LP Performance:
2025 Q3: 34.92%YTD: 23.44%2024: -2.02%
Performance for 2025 Q3 is 34.92%, and YTD is 23.44%, and 2024 is -2.02%.
About Lynx1 Capital Management LP and 13F Hedge Fund Stock Holdings
Lynx1 Capital Management LP is a hedge fund based in SAN JUAN, PR. On 03-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $136.4 Millions. In it's latest 13F Holdings report, Lynx1 Capital Management LP reported an equity portfolio of $491.3 Millions as of 30 Sep, 2025.
The top stock holdings of Lynx1 Capital Management LP are MRUS, STOK, . The fund has invested 29.4% of it's portfolio in MERUS N V and 22.4% of portfolio in STOKE THERAPEUTICS INC.
The fund managers got completely rid off PASSAGE BIO INC (PASG), UPSTREAM BIO INC and ASSEMBLY BIOSCIENCES INC (ASMB) stocks. They significantly reduced their stock positions in ALLOGENE THERAPEUTICS INC (ALLO), IBIO INC (IBIO) and PROTAGONIST THERAPEUTICS INC (PTGX). Lynx1 Capital Management LP opened new stock positions in ADC THERAPEUTICS SA (ADCT), PASSAGE BIO INC (PASG) and DENALI THERAPEUTICS INC (DNLI). The fund showed a lot of confidence in some stocks as they added substantially to CULLINAN THERAPEUTICS INC (CGEM), GH RESEARCH PLC and PRECISION BIOSCIENCES INC (DTIL).
The top stock holdings of Lynx1 Capital Management LP are MRUS, STOK, . The fund has invested 29.4% of it's portfolio in MERUS N V and 22.4% of portfolio in STOKE THERAPEUTICS INC.
The fund managers got completely rid off PASSAGE BIO INC (PASG), UPSTREAM BIO INC and ASSEMBLY BIOSCIENCES INC (ASMB) stocks. They significantly reduced their stock positions in ALLOGENE THERAPEUTICS INC (ALLO), IBIO INC (IBIO) and PROTAGONIST THERAPEUTICS INC (PTGX). Lynx1 Capital Management LP opened new stock positions in ADC THERAPEUTICS SA (ADCT), PASSAGE BIO INC (PASG) and DENALI THERAPEUTICS INC (DNLI). The fund showed a lot of confidence in some stocks as they added substantially to CULLINAN THERAPEUTICS INC (CGEM), GH RESEARCH PLC and PRECISION BIOSCIENCES INC (DTIL).
Lynx1 Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lynx1 Capital Management LP made a return of 34.92% in the last quarter. In trailing 12 months, it's portfolio return was 3.07%.
New Buys
| Ticker | $ Bought |
|---|---|
| adc therapeutics sa | 5,303,390 |
| passage bio inc | 5,008,340 |
| denali therapeutics inc | 3,799,700 |
New stocks bought by Lynx1 Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| cullinan therapeutics inc | 31.02 |
| gh research plc | 27.48 |
| precision biosciences inc | 0.63 |
Additions to existing portfolio by Lynx1 Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| allogene therapeutics inc | -95.06 |
| ibio inc | -31.37 |
| protagonist therapeutics inc | -4.5 |
| merus n v | -2.21 |
Lynx1 Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| passage bio inc | -3,705,560 |
| upstream bio inc | -2,407,330 |
| neuphoria therapeutics inc | -325,223 |
| assembly biosciences inc | -187,832 |
Lynx1 Capital Management LP got rid off the above stocks
Sector Distribution
Lynx1 Capital Management LP has about 78.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 78.8 |
| Others | 21.2 |
Market Cap. Distribution
Lynx1 Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 39.6 |
| SMALL-CAP | 35.6 |
| UNALLOCATED | 22.3 |
| MICRO-CAP | 2.3 |
Stocks belong to which Index?
About 39.8% of the stocks held by Lynx1 Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 60.2 |
| RUSSELL 2000 | 39.8 |
Lynx1 Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lynx1 Capital Management LP
Lynx1 Capital Management LP has 14 stocks in it's portfolio. About 98.8% of the portfolio is in top 10 stocks. CGEM proved to be the most loss making stock for the portfolio. MRUS was the most profitable stock for Lynx1 Capital Management LP last quarter.
Last Reported on: 13 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADCT | adc therapeutics sa | 1.08 | 1,325,850 | 5,303,390 | new | |||
| ALLO | allogene therapeutics inc | 0.14 | 546,119 | 677,188 | reduced | -95.06 | ||
| ASMB | assembly biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CCCC | c4 therapeutics inc | 3.21 | 7,098,130 | 15,757,900 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 6.96 | 5,766,090 | 34,192,900 | added | 31.02 | ||
| DNLI | denali therapeutics inc | 0.77 | 261,687 | 3,799,700 | new | |||
| DSGN | design therapeutics inc | 0.10 | 65,954 | 496,634 | unchanged | 0.00 | ||
| DTIL | precision biosciences inc | 1.17 | 1,042,600 | 5,755,130 | added | 0.63 | ||
| IBIO | ibio inc | 0.18 | 1,055,900 | 874,072 | reduced | -31.37 | ||
| MRUS | merus n v | 29.40 | 1,534,140 | 144,439,000 | reduced | -2.21 | ||
| PASG | passage bio inc | 1.02 | 623,704 | 5,008,340 | new | |||
| PASG | passage bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PTGX | protagonist therapeutics inc | 9.46 | 700,014 | 46,501,900 | reduced | -4.5 | ||
| STOK | stoke therapeutics inc | 22.36 | 5,404,670 | 109,881,000 | unchanged | 0.00 | ||
| TCRX | tscan therapeutics inc | 2.91 | 7,857,350 | 14,300,400 | unchanged | 0.00 | ||
| gh research plc | 21.23 | 8,601,190 | 104,312,000 | added | 27.48 | |||
| upstream bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | |||
| neuphoria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | |||